Together with the reduction in PD-L1 and IDO in SOX2-positive cells, these results highlight CBD’s multifaceted approach in targeting immune evasion, tumor growth, and treatment resistance, offering a comprehensive strategy to enhance the efficacy of existing therapies and improve long-term outcomes for GBM patients. This evidence concerns the gene CD274 and glioblastoma.